A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

320

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions

Delayed Graft FunctionEnd Stage Renal DiseaseDeceased Donor Kidney Transplant

Interventions

DRUG

Pegcetacoplan

Complement (C3) Inhibitor

OTHER

Placebo

Sterile solution of equal volume to active arm